How can stable, site-specific antibody conjugates be generated without recombinant DNA technology?
Our article presents a non-genetic, chemoenzymatic approach to antibody conjugation based on tyrosine click chemistry. Using a straightforward two-stage process—antibody deglycosylation followed by tyrosinase-mediated strain-promoted click chemistry—the method enables the efficient generation of homogeneous and stable antibody conjugates.
The technology is validated through the clean and reproducible production of DAR2 and DAR4 antibody–drug conjugates (ADCs) carrying clinically relevant cytotoxic payloads, including MMAE and PBD dimer. In vitro data demonstrate high potency and controlled conjugation, addressing key limitations of traditional stochastic and reduction-based ADC technologies.
Download the article to learn how chemoenzymatic tyrosine click chemistry enables precisely defined antibody conjugates for applications spanning diagnostics, imaging, and next-generation therapeutics.
